BALTIMORE, June 13, 2016 /PRNewswire/ -- Personal Genome Diagnostics Inc. (PGDx), a provider of advanced cancer genome testing products and services, today announced that co-founders Luis Diaz, MD, and Victor Velculescu, MD, PhD, have won the EY Entrepreneur Of The Year®2016 Award in the Maryland region.
This year marks the 30th anniversary of the EY Awards program, which recognizes entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment to their businesses and communities. Drs. Diaz and Velculescu were selected for the top honor in the Innovative Technology category by a panel of independent judges based on their ability to inspire others with their vision, leadership and achievement.
Drs. Diaz and Velculescu commented, "On behalf of our colleagues at PGDx, we are honored to have been selected as winners of this prestigious award that celebrates successful entrepreneurs who also demonstrate a commitment to their employees and communities. We founded PGDx with a mission to provide broad patient access to the pioneering cancer genomics technologies that we and our colleagues were developing at Johns Hopkins. Today we are more than 60 strong and offer a growing menu of state-of-the art, high quality cancer DNA testing services to a diverse customer base that includes researchers, drug developers, molecular testing labs and physicians and patients."
PGDx offers a complete range of cancer genome analysis tools, including exome and targeted approaches for tissue specimens, targeted approaches for plasma samples and a variety of custom tissue and plasma-based options designed to address the specific needs of cancer researchers and drug developers. It was established in 2010 by researchers from Johns Hopkins University who are pioneers in cancer genome sequencing and liquid biopsy technologies. The company has achieved consistent growth by successfully commercializing novel clinical and investigational products and services for researchers, drug developers, molecular testing laboratories, and physicians and patients.
Drs. Diaz and Velculescu continued, "We are proud of our team's progress in advancing the understanding of cancer and facilitating the development of new diagnostics and therapeutics with our comprehensive range of advanced cancer genome analysis tools. As part of our drive to increase patient and physician access to these potentially life-saving technologies, we are especially excited about PGDx's PROGENUS initiative, an innovative turnkey technology transfer solution that enables local and regional molecular laboratories to easily internalize and offer advanced genomic testing. Finally, we remain committed to building a successful business here in Baltimore, a city with a world class research university, rich cultural resources, great location and much else to offer new technology enterprises."
Founded and produced by Ernst & Young, EY Entrepreneur Of The Year is one of the world's most prestigious business awards for entrepreneurs. The award celebrates those who are building and leading successful, growing and dynamic businesses globally, through regional, national and global awards programs in more than 145 cities in 60 countries.
About Personal Genome Diagnostics Personal Genome Diagnostics (PGDx) advances the frontiers of cancer medicine through innovative genomic technologies for oncology researchers, drug developers, clinicians and patients. The expert team at PGDx draws on a deep understanding of cancer biology, extensive experience in cancer genomics and clinical oncology, and the company's distinctive technologies. These novel technologies precisely identify and characterize unique genomic alterations in tumors. PGDx is working toward broad patient access to its genomic approaches, through both a CLIA-certified facility providing comprehensive genomic services, as well as a technology transfer solution enabling other molecular laboratories to easily internalize testing. For additional information, visit personalgenome.com.